Table 3.

Treatment of MIS-C

Study	Cohort location	N	IVIG (%)	Glucocorticoids (%)	Other treatments	Ref.
Dufort et al.	USA	99	70	64	NR	14
Cheung et al.	USA	17	77	82	Tocilizumab, 6%	15
Belhadjer et al.	France, Switzerland	35	72	34	Anakinra, 9%	122
Kaushik et al.	USA	33	54	51	Tocilizumab, 36%; remdesivir, 21%; anakinra, 12%; convalescent plasma therapy, 3%	125
Davies et al.	UK	78	76	73	Tocilizumab, 4%; anakinra, 10%; infliximab, 9%; rituximab, 1%	126
Pouletty et al.	France	16	94	18.8	Tocilizumab, 6%; anakinra, 6%; hydroxychloroquine, 6%	127
Toubiana et al.	France	21	100	33	NR	128
Capone et al.	USA	33	100	70	Tocilizumab, 9%; anakinra, 12%; infliximab, 3%	129
Hameed et al.	UK	35	100	100	NR	130
Whittaker et al.	UK	58	71	64	Anakinra, 5%; infliximab, 14%	131
Moraleda et al.	Spain	31	65	68	Remdesivir, 6%	132
Dhanalakshmi et al.	India	19	79	58	Tocilizumab, 5%	133
Miller et al.	USA	44	82	96	Anakinra, 18%	134
Lee et al.	USA	28	71	61	Anakinra, 18%	136
Riollano-Cruz et al.	USA	15	80	20	Tocilizumab, 80%; remdesivir, 13%; anakinra, 13%; convalescent plasma therapy, 6%	137
Ramcharan et al.	UK	15	66	33	NR	138
Grimaud et al.	France	20	100	10	Tocilizumab, 10%; anakinra, 10%	139
Jonat et al.	USA	54	83	79	NR	205
Feldstein et al.	USA	186	77	49	Anakinra, 13%	13
Toubiana et al.	France	23	100	61	NR	236
García-Salido et al.	Spain	61	45	80	Tocilizumab, 24%; hydroxychloroquine, 55%	145
Shobhavat et al.	India	21	52	86	Tocilizumab, 10%	261
Niño-Taravilla et al.	Chile	26	77	88	Tocilizumab, 12%; infliximab, 4%	262
Tolunay et al.	Turkey	52	93	71	Anakinra, 4%	263

IVIG, intravenous immunoglobulin; MIS-C, multisystem inflammatory syndrome in children; NR, not reported.